JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. uri icon

Overview

authors

  • McKenney, Anna Sophia
  • Lau, Allison N
  • Somasundara, Amritha Varshini Hanasoge
  • Spitzer, Barbara
  • Intlekofer, Andrew Michael
  • Ahn, Jihae
  • Shank, Kaitlyn
  • Rapaport, Franck T
  • Patel, Minal A
  • Papalexi, Efthymia
  • Shih, Alan H
  • Chiu, April
  • Freinkman, Elizaveta
  • Akbay, Esra A
  • Steadman, Mya
  • Nagaraja, Raj
  • Yen, Katharine
  • Teruya-Feldstein, Julie
  • Wong, Kwok-Kin
  • Rampal, Raajit
  • Vander Heiden, Matthew G
  • Thompson, Craig B
  • Levine, Ross L.

publication date

  • September 17, 2018

Identity

PubMed Central ID

  • PMC6159958

Scopus Document Identifier

  • 85054445731

Digital Object Identifier (DOI)

  • 10.1172/JCI124920

PubMed ID

  • 30222137

Additional Document Info

volume

  • 128

issue

  • 10